Top line data for jaguar health's pivotal phase 3 ontarget trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy forthcoming

San francisco, ca / accesswire / november 21, 2023 / napo pharmaceuticals (napo), a jaguar health, inc. (nasdaq:jagx) family company, today announced that the company has not yet been provided with results from the company's gcp (good clinical practice) vendors supporting napo's pivotal phase 3 ontarget trial. the trial is evaluating the company's plant-based prescription drug crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy, with or without standard chemotherapy.
JAGX Ratings Summary
JAGX Quant Ranking